Trying Tourette's device tested by Lewis Capaldi was the best day of my life
A Nottingham-developed wrist device, Neupulse, shows rapid tic reduction for some Tourette’s patients, transforming lives and prompting NHS adoption discussions. Early users report instant calm and life-changing relief, fueling hopes for broader clinical use despite regulatory hurdles. Trials indicate measurable tic reduction and qualitative improvements in daily activities, while charities note widespread positive experiences. The project has attracted investment, spawned a spin-out, and spurred planned UK-wide trials for related conditions. Regulatory and long-term effectiveness evidence remain the key next steps toward NHS integration.
Dive Deeper:
Katie, a 15-year-old from Hertfordshire, experienced severe tics from age seven that left her bedridden and disrupted sleep, eating, and school; she and her mum traveled to Nottingham to try Neupulse, which produced an instant calming effect and emotional relief for Katie on her first use.
The Neupulse device delivers electrical pulses to the median nerve at the wrist, with trials suggesting rhythmic stimulation can modulate brain activity related to movement and reduce tic frequency and intensity.
A 2023 UK clinical trial of 121 participants reported an average 25% reduction in tic frequency when using a prototype, signaling potential clinical value alongside interest from public figures like Lewis Capaldi who tested the device.
Developed by the University of Nottingham and Neurotherapeutics Ltd, the project has secured around £1 million in funding to commercialize Neupulse, which is marketed in two versions: Neupulse-C for wellness and Neupulse-M aimed at medical treatment pending regulatory approval.
Tourettes Action and NICE have endorsed the technology as promising but require more long-term evidence before NHS adoption; thousands of devices have already been sold, and university researchers aim to obtain regulatory approval within the next year or so.
Ollie, a 15-year-old from Cheshire later diagnosed with Functional Neurological Disorder, described how the device suddenly stopped his neck movements, illustrating compelling individual impact beyond classic Tourette’s cases.
Beyond Tourette’s, researchers are exploring the device for Parkinson’s tremors and potential UK-wide trials for anxiety and OCD, signaling broader applicability and ongoing development.